Mifegyne (Mifepristone)

Mifepristone, the active ingredient in Mifegyne, is a progesterone receptor antagonist presented as an oral tablet for systemic use. It is employed for the medical termination of intra‑uterine pregnancy up to ten weeks and, off‑label, for managing Cushing’s syndrome.

GNH USA supplies Mifegyne as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, offering batch‑tested, WHO‑GMP‑aligned product with full documentation, reliable logistics and regulatory support, ensuring consistent potency and safety across markets for global authorized medical use.

Mifegyne (mifepristone) acts as a progesterone receptor antagonist and is used in specific reproductive and endocrine indications. - Medical termination of intrauterine pregnancy (≤10 weeks): induces decidual breakdown, detaches the gestational sac and prepares the uterus for prostaglandin‑mediated expulsion. - Cushing's syndrome (off‑label): blocks progesterone receptors that modulate adrenal steroidogenesis, leading to decreased cortisol secretion in selected patients.

Mifegyne may cause a range of adverse reactions, which are categorised by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Vaginal bleeding: irregular or prolonged spotting. - Abdominal cramping: uterine pain or discomfort. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Severe infection: signs of sepsis after incomplete abortion. - Heavy hemorrhage: rapid blood loss requiring medical intervention. - Allergic reaction: rash, swelling, or anaphylaxis.

Before prescribing Mifegyne, clinicians should evaluate the following safety considerations. - Contraindication: confirmed or suspected ectopic pregnancy. - Contraindication: chronic adrenal insufficiency or uncontrolled hypertension. - Caution: use only within ten weeks gestation confirmed by ultrasound. - Monitoring: ensure availability of surgical or medical backup for incomplete abortion. - Patient counseling: inform about expected bleeding and need for follow‑up. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Mifegyne can interact with other medicines that affect hormonal pathways or hemostasis.

Major Interactions (Avoid): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce mifepristone exposure. - Anticoagulants (warfarin, direct oral anticoagulants): increased risk of bleeding.

Moderate Interactions (Monitor Closely): - Antifungal azoles (ketoconazole, fluconazole): may increase mifepristone levels. - Hormonal contraceptives: reduced effectiveness when used concurrently. - NSAIDs: may mask abdominal pain, requiring careful assessment.